S&P 500   3,003.36 (+0.57%)
DOW   26,790.46 (+0.08%)
QQQ   193.25 (+0.81%)
AAPL   240.79 (+1.85%)
MSFT   138.00 (+0.43%)
GOOGL   1,245.23 (+0.07%)
AMZN   1,782.37 (+1.41%)
CGC   20.51 (+1.48%)
NVDA   195.78 (+2.78%)
MU   44.93 (+3.36%)
GE   8.84 (-1.34%)
TSLA   251.45 (-2.14%)
AMD   32.20 (+3.97%)
T   38.34 (-0.34%)
F   9.02 (-2.90%)
ACB   3.73 (+1.36%)
BAC   30.99 (+2.08%)
GILD   65.18 (+0.42%)
S&P 500   3,003.36 (+0.57%)
DOW   26,790.46 (+0.08%)
QQQ   193.25 (+0.81%)
AAPL   240.79 (+1.85%)
MSFT   138.00 (+0.43%)
GOOGL   1,245.23 (+0.07%)
AMZN   1,782.37 (+1.41%)
CGC   20.51 (+1.48%)
NVDA   195.78 (+2.78%)
MU   44.93 (+3.36%)
GE   8.84 (-1.34%)
TSLA   251.45 (-2.14%)
AMD   32.20 (+3.97%)
T   38.34 (-0.34%)
F   9.02 (-2.90%)
ACB   3.73 (+1.36%)
BAC   30.99 (+2.08%)
GILD   65.18 (+0.42%)
Log in

Boston Therapeutics Stock Price, News & Analysis (OTCMKTS:BTHE)

$0.01
0.00 (0.00 %)
(As of 10/21/2019 08:59 AM ET)
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.01
Now: $0.01
$0.05
Volume38,700 shs
Average Volume11,133 shs
Market Capitalization$1.21 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.49
Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates include BTI-320, a non-systemic, carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based, injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also develops OxyFex, an oxygen delivery agent for ischemia and trauma for blood loss during surgery in veterinary medicine applications. In addition, it produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BTHE
CUSIPN/A
Phone603-935-9799

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30,000.00
Book Value($0.04) per share

Profitability

Net Income$-3,600,000.00
Net Margins-8,042.35%

Miscellaneous

Employees2
Market Cap$1.21 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive BTHE News and Ratings via Email

Sign-up to receive the latest news and ratings for BTHE and its competitors with MarketBeat's FREE daily newsletter.


Boston Therapeutics (OTCMKTS:BTHE) Frequently Asked Questions

What is Boston Therapeutics' stock symbol?

Boston Therapeutics trades on the OTCMKTS under the ticker symbol "BTHE."

How were Boston Therapeutics' earnings last quarter?

Boston Therapeutics Inc (OTCMKTS:BTHE) released its quarterly earnings results on Monday, May, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. The firm earned $0.01 million during the quarter. View Boston Therapeutics' Earnings History.

When is Boston Therapeutics' next earnings date?

Boston Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Boston Therapeutics.

Has Boston Therapeutics been receiving favorable news coverage?

Media coverage about BTHE stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Boston Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Boston Therapeutics.

Who are some of Boston Therapeutics' key competitors?

What other stocks do shareholders of Boston Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Therapeutics investors own include Dynavax Technologies (DVAX), NeXt Innovation (GSVC), Inpixon (INPX), Firsthand Technology Value Fund (SVVC), InterCloud Systems (ICLD), PositiveID (PSID), Vodafone Group (VOD), Arca Biopharma (ABIO), Apollo Investment (AINV) and Ambarella (AMBA).

Who are Boston Therapeutics' key executives?

Boston Therapeutics' management team includes the folowing people:
  • Mr. Carl W. Rausch, CEO, CFO & Director (Age 70)
  • Dr. Meng Hee Tan, Consulting Medical Director

How do I buy shares of Boston Therapeutics?

Shares of BTHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Boston Therapeutics' stock price today?

One share of BTHE stock can currently be purchased for approximately $0.01.

How big of a company is Boston Therapeutics?

Boston Therapeutics has a market capitalization of $1.21 million and generates $30,000.00 in revenue each year. Boston Therapeutics employs 2 workers across the globe.View Additional Information About Boston Therapeutics.

What is Boston Therapeutics' official website?

The official website for Boston Therapeutics is http://www.bostonti.com/.

How can I contact Boston Therapeutics?

Boston Therapeutics' mailing address is 354 MERRIMACK STREET #4, LAWRENCE MA, 01843. The company can be reached via phone at 603-935-9799 or via email at [email protected]


MarketBeat Community Rating for Boston Therapeutics (OTCMKTS BTHE)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Boston Therapeutics and other stocks. Vote "Outperform" if you believe BTHE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTHE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: What is the QQQ ETF?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel